5-Aminoisoquinoline → N-Isoquinolin-5-yl-1-(5-trifluoromethylpyrid-2-yl)-piperidine-4-carboxamide
반응식
[F:1][C:2]([F:19])([F:18])[C:3]1[CH:4]=[CH:5][C:6]([N:9]2[CH2:14][CH2:13][CH:12]([C:15]([OH:17])=O)[CH2:11][CH2:10]2)=[N:7][CH:8]=1.[NH2:20][C:21]1[CH:30]=[CH:29][CH:28]=[C:27]2[C:22]=1[CH:23]=[CH:24][N:25]=[CH:26]2>>[CH:26]1[C:27]2[C:22](=[C:21]([NH:20][C:15]([CH:12]3[CH2:11][CH2:10][N:9]([C:6]4[CH:5]=[CH:4][C:3]([C:2]([F:1])([F:19])[F:18])=[CH:8][N:7]=4)[CH2:14][CH2:13]3)=[O:17])[CH:30]=[CH:29][CH:28]=2)[CH:23]=[CH:24][N:25]=1참가 물질
3
실험 절차
Using the procedure outlined in Example 107, the title compound was prepared from 1-(5-trifluoromethylpyrid-2-yl)-piperidine-4-carboxylic acid (D101) (100 mg, 0.36 mmol) and 5-aminoisoquinoline (27 mg, 0.19 mmol) as an off white solid. MS(ES): MH+ 401, M-H+ 399.
출처 및 근거
- ORD 기록
- ord-c8a4397337eb4c0da914e85db52378b8
- 출처 데이터셋
- uspto-grants-2009_05